^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Anal Carcinoma |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) + Mitotie (mitomycin) (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
5-FU with MMC combined with radiotherapy are generally recommended, rather than 5-FU and cisplatin, MMC and cisplatin, any single drug or any combination of three drugs.
DOI:
doi:10.1093/annonc/mdu159
Source:
Title:
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial
Excerpt:
...Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal…The 5-year overall survival rate was 75% (95% CI, 67%-81%) in the mitomycin-based group and 70% (95% CI, 63%-76%) in the cisplatin-based group (P = .10).
DOI:
10.1001/jama.299.16.1914
Source:
Title:
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
Excerpt:
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus...with fluorouracil...3-year progression-free survival was 74% (95% CI 69-77; maintenance) versus 73% (95% CI 68-77; no maintenance; hazard ratio 0.95, 95% CI 0.75-1.21; p=0.70).
DOI:
10.1016/S1470-2045(13)70086-X
